Amgen Inc. [NASDAQ: AMGN] jumped around 4.08 points on Thursday, while shares priced at $244.72 at the close of the session, up 1.70%. The company report on May 12, 2022 that AMGEN AND LANCE BASS PARTNER TO ENCOURAGE PEOPLE TO DO A ‘DOUBLE TAKE’ TO RECOGNIZE THE EARLY SIGNS OF PSORIATIC ARTHRITIS.
Campaign Drives Awareness of Potential Early Symptoms of Psoriatic Arthritis and Empowers People to Take Action.
Amgen (NASDAQ:AMGN) and Otezla® (apremilast) have partnered with pop icon and entrepreneur Lance Bass, for the Double Take campaign to empower people to take action when it comes to psoriatic arthritis. As a singer, dancer and entertainer, Bass understands the importance of staying in tune with your body. Through the campaign, he has created a fun and educational dance to help make it easy for everyone to recognize the early signs and symptoms of psoriatic arthritis, a condition Bass has lived with for over a decade.
Amgen Inc. stock is now 8.78% up from its year-to-date (YTD) trading value. AMGN Stock saw the intraday high of $244.84 and lowest of $239.05 per share. The company’s 52-week high price is 258.45, which means current price is +14.15% above from all time high which was touched on 04/11/22.
Compared to the average trading volume of 3.17M shares, AMGN reached a trading volume of 3697076 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Amgen Inc. [AMGN]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AMGN shares is $248.99 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AMGN stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Wells Fargo have made an estimate for Amgen Inc. shares, keeping their opinion on the stock as Equal Weight, with their previous recommendation back on February 09, 2022. While these analysts kept the previous recommendation, Oppenheimer raised their target price from $272 to $285. The new note on the price target was released on February 09, 2022, representing the official price target for Amgen Inc. stock. Previously, the target price had yet another raise from $235 to $238, while Morgan Stanley kept a Equal-Weight rating on AMGN stock. On February 09, 2022, analysts increased their price target for AMGN shares from 266 to 280.
The Average True Range (ATR) for Amgen Inc. is set at 5.83, with the Price to Sales ratio for AMGN stock in the period of the last 12 months amounting to 4.92. The Price to Book ratio for the last quarter was 146.54, with the Price to Cash per share for the same quarter was set at 12.36. Price to Free Cash Flow for AMGN in the course of the last twelve months was 29.85 with Quick ratio for the last quarter at 1.10.
How has AMGN stock performed recently?
Amgen Inc. [AMGN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 4.43. With this latest performance, AMGN shares dropped by -2.13% in over the last four-week period, additionally plugging by 14.78% over the last 6 months – not to mention a drop of -2.92% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AMGN stock in for the last two-week period is set at 54.79, with the RSI for the last a single of trading hit 58.56, and the three-weeks RSI is set at 54.22 for Amgen Inc. [AMGN]. The present Moving Average for the last 50 days of trading for this stock 241.01, while it was recorded at 240.36 for the last single week of trading, and 224.68 for the last 200 days.
Amgen Inc. [AMGN]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Amgen Inc. [AMGN] shares currently have an operating margin of +35.22 and a Gross Margin at +75.16. Amgen Inc.’s Net Margin is presently recorded at +22.68.
Return on Equity for this stock inclined to 73.16, with Return on Assets sitting at 9.50.
Amgen Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.10 and a Current Ratio set at 1.40.
Earnings analysis for Amgen Inc. [AMGN]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AMGN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Amgen Inc. go to 7.07%.
Insider trade positions for Amgen Inc. [AMGN]
There are presently around $102,557 million, or 81.20% of AMGN stock, in the hands of institutional investors. The top three institutional holders of AMGN stocks are: BLACKROCK INC. with ownership of 50,028,170, which is approximately -0.036% of the company’s market cap and around 0.20% of the total institutional ownership; VANGUARD GROUP INC, holding 46,661,009 shares of the stock with an approximate value of $11.23 billion in AMGN stocks shares; and STATE STREET CORP, currently with $7.25 billion in AMGN stock with ownership of nearly 1.705% of the company’s market capitalization.
Positions in Amgen Inc. stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 1,140 institutional holders increased their position in Amgen Inc. [NASDAQ:AMGN] by around 20,492,277 shares. Additionally, 946 investors decreased positions by around 24,060,015 shares, while 329 investors held positions by with 381,630,080 shares. The mentioned changes placed institutional holdings at 426,182,372 shares, according to the latest SEC report filing. AMGN stock had 185 new institutional investments in for a total of 2,266,465 shares, while 104 institutional investors sold positions of 1,271,317 shares during the same period.